

IN COLLABORATION WITH INSIGHTS PARTNER MCKINSEY & COMPANY

## AGENDA AT-A-GLANCE

\*Schedule subject to change

			*Schedule subject to change
6/6 NOM		4:30 pm - 5:30 pm	<b>Heads of Pharma Research, in Conversation:</b> Biogen's Jane Grogan, Novartis' Fiona Marshall
		8:00 am - 8:45 am 8:45 am - 9:00 am 9:00 am - 10:00 am	Breakfast workshop: Overcoming company formation challenges Official Welcome from BioCentury  McKinsey & Company Conference Report: Reimagining translation: how to unlock the next wave of breakthrough treatments
TUES 9/10	GRAND ROUNDS I: Translational Bottlenecks	10:00 am - 10:40 am 11:10 am - 11:50 am 11:50 am - 12:30 pm	From causal biology to preclinical validation: What makes the grade in 2024?  The human first era is here: Is there still value in new animal models?  Delivery on demand: Still the elephant in the room
	GRAND ROUNDS II: The Modality Groundbreakers	1:30 pm - 2:10 pm 2:10 PM - 2:50 PM 3:20 pm - 4:00 pm 4:00 pm - 4:40 pm 4:40 pm - 5:30 pm 6:00 pm - 7:00 pm	The heyday of AAV engineering is here: Will it deliver?  The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox?  Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies?  Souping up cancer cell therapies: Is the juice worth the squeeze?  Closing the innovation gap: Partnerships for next-gen treatments  Poster Spotlight Presentations: At the Forefront of Translational Innovation
WED 9/11	GRAND ROUNDS III: The Human Data Revolution	9:00 am - 10:00 am 10:00 am - 10:40 am 11:10 am - 11:50 am	Keynote Address: Harvard's Greg Verdine on blowing up the small molecule paradigm  Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity  Data-for-purpose: Go big, go deep, or go long?
	GRAND ROUNDS IV: The Disease Biology Boom	11:50 am - 12:30 pm 12:30 pm - 1:30 pm 1:30 pm - 2:10 pm 2:10 pm -2:50 pm 2:50 pm - 3:30 pm	Unlocking progress in neurology: How to build the case for a new target Lunchtime Fireside Chat: Vanderbilt's Robert Carnahan & Arch Venture's Lu Borio Immunity and inflammation inflection point: What determines the direction from here? Hunger games: The incredible appetite for more innovation in obesity Closing Rapporteur Plenary: What's Next For Translational Research?



IN COLLABORATION WITH INSIGHTS PARTNER **MCKINSEY & COMPANY** 

## **SPEAKERS**

Learn from 50+ industry thought leaders, including:



Gonçalo Abecasis Regeneron



Amy Abernethy Former FDA



Luciana Borio Arch Venture Partners



Daniel Burkhardt Cellarity



Robert Carnahan Vanderbilt University



Zandy Forbes MeiraGTx



Kevin Friedman Kelonia Therapeutics



Chris Garabedian Perceptive Advisors



Andrei Georgescu Vivodyne



David Goldstein Actio Biosciences



Jane Grogan Biogen



Anika Gupta GV



Kristin Hege Former Bristol Myers Squibb



Colin Hill Aitia



Chris Hollowood Syncona



Sophie Kornowski Boston Pharmaceuticals



Erin Krimbel, Astellas



John Lepore ProFound Therapeutics



Patrick Lyden Keck School of Medicine of USC



Samuel Lynch VUMC



Mathai Mammen FogPharma



Fiona Marshall Novartis



Clare Murray Life Edit Therapeutics



**Gregory Newby** Johns Hopkins University



Stephanie Oestreich Myeloma Investment Fund



Deborah Palestrant 5AM Ventures



Nicole Paulk Siren Biotechnology



Daniel Reich NIH



Adam Savitz Alto Neuroscience



Samantha Singer Abata Therapeutics



Elizabeth Ann Stringer Nashville Biosciences



Paul Peter Tak Candel Therapeutics



Gregory Verdine Harvard University





Daniel von Bornstädt McKinsey & Company



Douglas Williams Sana Biotechnology



Carolyne Zimmermann SonoThera